NTLA
Intellia Therapeutics, Inc.
+1.09 (+9.49%)12.58USD3.2M成交股數1.8B市值–本益比(近四季)29.6股價營收比-46.2%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 7.7M-54% | 15.0M+17% | 13.8M+51% | 14.2M+105% | 16.6M-43% | 12.9M+7% | 9.1M-33% | 7.0M-45% | 28.9M | 12.0M | 13.6M | 12.6M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 82.6M | 80.7M | 94.7M | 97.0M | 108M | 117M | 123M | 114M | 112M | 114M | 115M | 97.1M |
| 銷售管理費用 | 37.8M | 34.8M | 30.5M | 27.2M | 29.0M | 32.4M | 30.5M | 31.8M | 31.1M | 29.4M | 30.7M | 27.4M |
| 營業利益 | −113M-7% | −101M-26% | −111M-23% | −110M-21% | −121M+6% | −136M+4% | −145M+9% | −139M+24% | −114M | −131M | −132M | −112M |
| 營業利益率 | -1,472.3% | -668.1% | -808.9% | -772.2% | -726.6% | -1,059.9% | -1,589.0% | -1,998.6% | -394.0% | -1,093.3% | -973.5% | -888.1% |
| 稅後淨利 | −107M-7% | −96.2M-25% | −101M-25% | −101M-31% | −114M+6% | −129M+5% | −136M+10% | −147M+43% | −107M | −122M | −124M | −103M |
| 淨利率 | -1,392.3% | -639.5% | -735.2% | -710.8% | -687.6% | -1,001.2% | -1,489.5% | -2,112.6% | -371.3% | -1,019.2% | -909.8% | -818.1% |
| 稀釋 EPS | -0.80-27% | -0.81-36% | -0.92-31% | -0.98-36% | -1.10-2% | -1.27-8% | -1.34-4% | -1.52+30% | -1.12 | -1.38 | -1.40 | -1.17 |
| 稀釋股數 | 133M | 118M | 110M | 104M | 104M | 98.8M | 101M | 97.0M | 95.5M | 88.6M | 88.2M | 87.8M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 106M | 135M | 193M | 156M | 127M | 189M | 120M | 131M | 172M | 168M | 172M | 294M |
| 應收帳款 | 7.3M | 9.1M | 11.1M | 11.4M | 10.5M | 8.5M | 8.9M | 12.3M | 36.4M | 6.5M | 5.1M | 4.9M |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 857M | 759M | 925M | 899M | 986M | 1.2B | 1.2B | 1.2B | 1.3B | 1.2B | 1.3B | 1.4B |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 129M | 138M | 177M | 184M | 206M | 319M | 211M | 220M | 223M | 206M | – | – |
| 股東權益 | 728M | 621M | 748M | −715M | 780M | 872M | 963M | 971M | 1.0B | 1.0B | 1.1B | 1.2B |
| 負債比 | 15.1% | 18.2% | 19.1% | 20.4% | 20.9% | 26.8% | 18.0% | 18.5% | 17.7% | 16.6% | – | – |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q3 | 25Q2 | 25Q1 | 24Q4 | 24Q3 | 24Q2 | 24Q1 | 23Q3 | 23Q2 | 23Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −117M | – | – | −149M+23% | – | – | – | −121M | – | – | −109M |
| 資本支出 | – | 79K | – | – | 735K | – | – | – | 2.5M | – | – | 3.8M |
| 自由現金流 | – | −117M | – | – | −150M+22% | – | – | – | −123M | – | – | −113M |
| 折舊攤銷 | 2.1M | 2.2M | 2.4M | 2.5M | 2.5M | 2.6M | 2.6M | 2.6M | 2.5M | – | – | 2.1M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -780.3% | – | – | -900.1% | – | – | – | -425.7% | – | – | -897.7% |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 67.7M | +16.9% | −413M | -609.9% | -3.81 | −396M |
| FY2024 | 57.9M | +59.6% | −519M | -896.8% | -5.25 | −355M |
| FY2023 | 36.3M | -30.4% | −481M | -1,326.5% | -5.42 | −408M |
| FY2022 | 52.1M | +57.7% | −474M | -909.8% | -6.16 | −347M |
| FY2021 | 33.1M | -43.0% | −268M | -810.5% | -3.78 | −238M |
| FY2020 | 58.0M | +34.5% | −134M | -231.5% | -2.40 | −53.5M |
| FY2019 | 43.1M | +41.6% | −474M | -1,100.1% | -2.11 | −110M |
| FY2018 | 30.4M | – | −85.3M | -280.4% | -1.98 | −67.6M |